Asthma Patient Airway Sample Collection Study Completed
Study Overview
This study, initiated on June 2, 1999, is now a completed clinical trial sponsored by the National Institute of Cardiology, Pulmonology and Hematology. Using fiberoptic bronchoscopy, bronchial brushing and bronchoalveolar lavage were performed on asthma patients and healthy volunteers. This enabled direct collection and analysis of airway inflammatory cells and fluids.
Clinical Significance
Although asthma is treated with inhaled steroids, β2‑agonists, and other established therapies, inflammatory phenotypes vary among patients, leading to heterogeneous treatment responses. Detailed characterization of inflammatory cell subsets and cytokine profiles from airway samples can inform the development of personalized therapeutic strategies.
Biopharma Linkage
The harvested cellular and liquid specimens are suitable for transcriptomic, proteomic, and metabolomic analyses, supporting the discovery of novel anti‑inflammatory agents and biomarkers. Companies developing asthma therapeutics—such as anti‑IL‑5 or stem cell growth factor modulators—can leverage these data for target validation and patient stratification.
Investment & Market Outlook
The global asthma market is approximately $26 billion, with biologics experiencing rapid growth. High‑resolution data increase the probability of drug success and reduce the cost of failed trials, thereby enhancing investment attractiveness.
The study provides high‑resolution data on airway inflammation mechanisms, strengthening target validation and clinical success probabilities for new drugs, which in turn elevates investment value. Talent capable of applying emerging biomarkers and sample‑analysis technologies is in demand.
Source: ClinicalTrials.gov (api_ct)